Table 2.
Summary of PSA, PSA doubling time (12 definitions), and PSA velocity (10 definitions), calculated at the time of diagnosis.
| Number of patients with calculable value |
Median (interquartile range) or Frequency (percentage) |
|
|---|---|---|
| Total PSA, ng/mL | 594 (100%) | 17 (9, 33) |
| Doubling Time, months | ||
| MSKCC26 | 565 (95%) | 6 (−5, 26) |
| Shulman18 | 561 (94%) | 4 (−3, 13) |
| MD Anderson 216 | 553 (93%) | 3 (−4, 12) |
| MD Anderson 116 | 545 (92%) | 2 (−4, 11) |
| Ward21 | 350 (59%) | 1 (−1, 2) |
| Freedland14 | 327 (55%) | 13 (0, 30) |
| Egawa13 | 210 (35%) | 22 (7, 45) |
| Trapasso22 | 194 (33%) | 1 (0, 3) |
| Stephenson20 | 135 (23%) | 0 (−1, 2) |
| Hanks15 | 112 (19%) | 32 (8, 60) |
| Smith19 | 59 (10%) | 30 (16, 50) |
| D’Amico12 | 40 (7%) | 3 (1, 5) |
| Velocity, ng/mL/yr | ||
| MSKCC26 | 594 (100%) | 0.01 (−0.02, 0.05) |
| Thompson25 | 589 (99%) | 0.01 (−0.02, 0.05) |
| D’Amico A4 | 492 (83%) | 0.33 (−0.50, 1.45) |
| D’Amico A >2 ng/mL/yr4 | 492 (83%) | 105 (21%) |
| Rozhansky23 | 369 (62%) | 0.30 (−0.90, 2.03) |
| Sengupta17 | 327 (55%) | 0.02 (−0.01, 0.04) |
| D’Amico B5 | 90 (15%) | 0.35 (0.08, 0.90) |
| D’Amico B >2 ng/mL/yr5 | 90 (15%) | 8 (9%) |
| Thiel24 | 82 (14%) | 0.15 (0.02, 0.41) |
| Smith19 | 59 (10%) | 0.02 (0.01, 0.03) |